Oxytocin's Effect on the Advantageous- and Disadvantageous-inequity

NCT ID: NCT06405737

Last Updated: 2024-08-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-07
• Study Completion Date: 2024-06-20

Brief Summary

The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and whether oxytocin has similar effects on them or not.

Detailed Description

The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and its underlying neural mechanisms and whether oxytocin has similar effects on them or not. A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. A modified inequity decision-making task starts 45 minutes after treatment with behavioral (fairness rating, preference rating and the choice rate of unequal option) and fMRI data being collected during this task. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the task.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

oxytocin

a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.

Group Type: EXPERIMENTAL

Intranasal oxytocin

Intervention Type: DRUG

Subject assigned to receive intranasal administration of oxytocin (24 IU).

placebo

a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.

Group Type: EXPERIMENTAL

Intranasal placebo

Intervention Type: DRUG

Subjects assigned to receive intranasal administration of placebo (24 IU).

Interventions

Intranasal oxytocin

Subject assigned to receive intranasal administration of oxytocin (24 IU).

Intervention Type: DRUG

Intranasal placebo

Subjects assigned to receive intranasal administration of placebo (24 IU).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy subjects without past or current psychiatric or neurological disorders

Exclusion Criteria

• history of head injury
• pregnant,menstruating,taking oral contraceptives
• medical or psychiatric illness.
• excessive head movement (> 3mm) during scanning

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Electronic Science and Technology of China

OTHER

Sponsor Role: lead

Responsible Party

Shuxia Yao

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yao Shuxia, Dr

Role: PRINCIPAL_INVESTIGATOR

University of Electronic Science and Technology of China

Locations

University of Electronic Science and Technology of China (UESTC)

Chengdu, Sichuan, China

Countries

China

Other Identifiers

UESTC-neuSCAN-88

Identifier Type: -

Identifier Source: org_study_id